Calidi Biotherapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-4.2M | $-4.1M | $-5.1M | $-5.7M | $-5.0M | $-5.1M | $-5.8M | $-7.2M |
| Depreciation & Amortization | — | $426.0K | — | — | $394.0K | — | — | — |
| Depreciation | — | — | — | — | $91.0K | $100.0K | $100.0K | $102.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $231.0K | — | — | $607.0K | — | — | $888.0K |
| Net Cash from Operating Activities | $-4.4M | $-4.1M | $-4.2M | $-4.9M | $-7.1M | $-4.9M | $-5.5M | $-3.8M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-5.0K | — | — | $-7.0K | — | — | $-5.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $5.2M | — | — | $8.1M | — | — | $3.0M |
| Net Change in Cash | — | $1.0M | — | — | $970.0K | — | — | $-806.0K |
| Free Cash Flow | — | — | — | — | — | — | — | — |